FBIO
Fortress Biotech Inc
2.10$
+2.5%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | 5,952.3% | 68.9% | 85.9% | 22.8% | 28.8% | 32.0% | 46.6% | 40.6% | 27.1% | 36.2% | 33.1% | |
| – | – | – | – | – | – | – | 100.0% | 31.1% | 14.1% | 77.2% | 71.2% | 68.0% | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% | |
| – | – | – | – | – | – | – | 3,454.2% | 213.2% | 28.0% | 325.1% | 222.0% | 140.6% | 187.3% | 178.1% | 125.5% | 98.6% | 18.8% | |
| – | – | – | – | – | – | – | 2,501.0% | 188.8% | 38.9% | 198.5% | 151.8% | 134.1% | 126.2% | 150.1% | 118.0% | 152.1% | 152.4% | |
| – | – | – | – | – | – | – | 5,955.3% | 429.9% | 68.0% | 523.6% | 373.8% | 274.7% | 327.4% | 328.1% | 241.3% | 255.2% | 177.9% | |
| – | – | – | – | – | – | – | -5,855.3% | -398.7% | -47.9% | -446.4% | -302.5% | -206.7% | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% | |
| – | – | – | – | – | – | – | 172.0% | 22.4% | 4.1% | 38.5% | 32.3% | 33.6% | 22.3% | 18.0% | 14.8% | 17.2% | 13.8% | |
| – | – | – | – | – | – | – | -6,243.7% | -432.6% | -52.4% | -486.6% | -277.5% | -225.6% | -238.9% | -281.8% | -181.8% | -209.0% | -53.0% | |
| – | – | – | – | – | – | – | -463.2% | -75.9% | 0.8% | -1.7% | -136.1% | 0.3% | 0.7% | 0.6% | 0.6% | 0.5% | -1.0% | |
| – | – | – | – | – | – | – | -5,611.6% | -334.3% | -35.7% | -313.0% | -109.1% | -102.0% | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% | |
| – | – | – | – | – | – | – | -6,068.7% | -405.8% | -47.2% | -440.4% | -241.6% | -192.6% | -212.5% | -255.7% | -160.6% | -181.2% | -31.9% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.